In GSDME-expressing melanoma, the combination of BRAF inhibitors and MEK inhibitors treatment, FDA-approved therapy for BRAF V600E/K mutant melanoma, activates caspase-3 and triggers GSDME pyroptosis. Here, MAP2K7 is linked to melanoma.